Canonical pathways identified by ingenuity pathway analysis of statistically significant genes (P < 0.01, without FDR correction) and a more than 1.2-fold difference between TP-10 and vehicle-treated mouse striatum or between PDE10 KO and WT mouse striatum
Genes used for pathway analysis are listed in Supplementary Table 1. Pathways identified in bold text were determined to be significantly affected in both comparisons.
| TP-10 vs. vehicle treated mouse striatum | P Value | PDE10 knockout vs. WT mouse striatum | P Value |
|---|---|---|---|
| Alanine and aspartate metabolism | 0.003 | Protein kinase A signaling | 0.003 |
| GABA receptor signaling | 0.003 | p38 MAPK signaling | 0.003 |
| Mitotic roles of polo-like kinase | 0.007 | ERK/MAPK signaling | 0.009 |
| Aryl hydrocarbon receptor signaling | 0.009 | Calcium-induced T lymphocyte apoptosis | 0.015 |
| Axonal guidance signaling | 0.009 | Mitotic roles of polo-like kinase | 0.020 |
| Taurine and hypotaurine metabolism | 0.010 | Growth hormone signaling | 0.026 |
| Glutamate metabolism | 0.012 | ERK5 signaling | 0.026 |
| Cyanoamino acid metabolism | 0.020 | Cardiac β-adrenergic signaling | 0.035 |
| Nitrogen metabolism | 0.022 | Reelin signaling in neurons | 0.042 |
| Cardiac β-adrenergic signaling | 0.022 | ||
| Calcium signaling | 0.023 | ||
| Hepatic fibrosis/hepatic stellate cell activation | 0.026 | ||
| Ephrin receptor signaling | 0.028 | ||
| β-alanine metabolism | 0.031 | ||
| Gβγ signaling | 0.032 | ||
| Synaptic long term depression | 0.035 | ||
| Protein kinase A signaling | 0.035 | ||
| p38 MAPK signaling | 0.038 | ||
| Type I diabetes mellitus signaling | 0.039 | ||
| Butanoate metabolism | 0.047 |